Loading…
← CockpitCompetitor Analysis › SHILPAMED.NS Shilpa Medicare LimitedOpen in the cockpit ↗

Shilpa Medicare LimitedSHILPAMED.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Manufactures active pharmaceutical ingredients and formulations, with a focus on oncology drugs, for global markets.

≈ A niche Indian oncology API/formulations makerMomentum leader 95
Mkt cap
$1.91B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$7.71M
20-day average traded
Fwd P/E
54.3×
forward earnings
ROIC−WACC
-1.7 pp
WACC 10.2%
Hurdle
n/a
no reverse DCF
Next earnings
79 days
5 Feb 2027
Close · INR₹915.30
1D-0.2%
1W-2.0%
1M+4.5%
3M+13.0%
6M+93.7%
YTD+185.0%
1Y+128.9%
ATR %5.4%
Beta0.72
52w lowhigh16.4% off high

What Shilpa Medicare does

Manufactures active pharmaceutical ingredients and formulations, with a focus on oncology drugs, for global markets.

Sells cancer-drug ingredients by the batch to generic makers, which also gives it a base for its own finished formulations, and contract manufacturing for other companies adds a second revenue source. Its biosimilars, copies of biologic drugs, are separate and need regulatory approvals before they can sell.

In one line: A niche Indian oncology API/formulations maker.

Products and services

  • Oncology APIs
  • Formulations
  • Biosimilars pipeline

Customers

  • Global generic drug makers
  • Hospitals/oncology distributors

Where it sits in the supply chain

  • API/formulation R&D
  • Oncology API manufacturing
  • Global pharma distribution

What could go right

  • Global oncology generics growth
  • Biosimilar approvals

What could go wrong

  • Regulatory/compliance risk
  • Customer concentration

Moat: narrow (regulatory licence, process know-how). Specialized oncology API manufacturing (cytotoxic handling) requires regulatory approvals rivals lack.

Headquarters: Raichur, India · Founded: 1987 · Employees: 1,132

Named competitors

Shilpa Medicare at a glance

Size Shilpa Medicare (SHILPAMED.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.91B, the 390th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹915.30 on 18 Nov 2026.

Performance Over six months the shares gained 93.7%, against -9.3% for the median peer and +3.8% for the India market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 37.3% over the last twelve months (peer median +10.7%); the operating margin is 20.9% (peer median 17.9%).

Valuation It trades at 54.3× forward earnings against a peer median of 16.9× (3rd most expensive of 17).

Capital Return on invested capital runs 1.7 points below its cost of capital (10.2% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026SHILPAMED.NS 192Peer median 91
Six months, rebased to 100: Shilpa Medicare against the median of its 20 peers (local-currency closes).

Shilpa Medicare financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹18.4B₹15.4B₹12.8B₹11.5B₹10.4B
Revenue growth—+20%+12%+10%—
Gross profit₹7.45B₹4.93B₹3.62B₹2.55B₹1.34B
EBITDA₹5.14B₹3.84B₹3.08B₹2.38B₹858M
Net income₹3.32B₹2.43B₹783M₹319M-₹325M
Free cash flown/a-₹754M-₹1.80B-₹1.39B-₹1.03B
Capital expendituren/a₹3.71B₹2.44B₹1.85B₹2.27B
Total debt₹6.66B₹6.60B₹5.88B₹9.37B₹7.98B

Quarterly statements and history in the cockpit →

Shilpa Medicare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-10%0%+10%+20%0512ALIVUS4540600201HRMYONESOURCEBHVNPFIZER600211COHANCE000908DMPERIS3005739969009420605507000028300436SHILPAMED.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Shilpa Medicare is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%50×100×0512ALIVUS4540600201ONESOURCEPFIZER300009COHANCEERIS9969SHILPAMED.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shilpa Medicare is the large dot.

Shilpa Medicare competitors and peer comparison

Head to head with its named competitors (SHILPAMED.NS vs NATCOPHARM.NS vs BIOCON.NS vs DRREDDY.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shilpa Medicare SHILPAMED.NS$1.91B+94%+37%21%54.3×n/a
NATCO Pharma NATCOPHARM.NS$1.73B-27%-30%17%19.1×20.5%
Biocon BIOCON.NS$6.31B-15%+6%8%61.3×n/a
Dr. Reddy's Laboratories DRREDDY.NS$12.5B+5%-4%9%32.0×30.7%

How Shilpa Medicare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shilpa Medicare against its 20 peers (data as of 18 Nov 2026)
MeasureSHILPAMED.NSPeer medianRank in peer set
1-month return+4.5%+0.7%9th highest of 21
6-month return+93.7%-9.3%highest of 21
Distance from 52-week high-16.4%-28.8%4th highest of 21
Revenue growth (TTM)+37.3%+10.7%2nd highest of 20
Operating margin20.9%17.9%10th highest of 20
Forward P/E54.3×16.9×3rd most expensive of 17
ROIC minus cost of capital-1.7 pp+1.4 pp7th lowest of 20
EV / EBITDA36.0×15.0×3rd most expensive of 10
Net debt / EBITDA1.2×1.3×6th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a

Questions

Who are Shilpa Medicare's main competitors?
Named competitors: Natco Pharma (NATCOPHARM.NS), Biocon (BIOCON.NS), Dr. Reddy's (DRREDDY.NS). The cockpit's measured peer set (industry) also includes Grand Pharmaceutical (0512.HK), Alivus Life Sciences (ALIVUS.NS), Tsumura & (4540.T), Jinyu Bio-Technology (600201.SS), Harmony Biosciences (HRMY), OneSource Specialty Pharma (ONESOURCE.NS).
Is Shilpa Medicare expensive compared with its peers?
On forward p/e it trades at 54.3× against a peer median of 16.9×, 3rd most expensive of 17 in its peer set.
How has Shilpa Medicare stock performed?
Over six months to 18 Nov 2026 the shares returned +93.7% against -9.3% for the median peer; over one year +128.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.